These findings indicate that the targeted HRP formulation successfully recognized estrogen receptors on breast cancer cells and released more DOX under tumor hypoxia, enhancing the anticancer effect of DOX and effectively alleviating chemotherapy resistance (98). Here, ESR1 is linked to breast carcinoma.